Toxicological Sciences · 2014 · 58 citations · 44 references
Life SciencesCardiologyPharmacologyCellular MetabolismMitochondrial BiologyMolecular PharmacologyMitochondrial DysfunctionMitochondrial MetabolismMitochondrial PhysiologyMitochondrial Stress ResponsesMitochondrial ToxicityReactive Oxygen SpeciesCardiac Mitochondrial FunctionCardiotoxicityMitochondrial Function In CardiomyocytesMitochondrial Oxidative StressMyocardial Energy MetabolismPeroxisome Proliferator-activated Receptor Gamma AgonismPeroxisome Proliferator-activated Receptor-mediated ToxicityPeroxisome Proliferator-activated Receptors
This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor γ (PPARγ) agonist, causes cardiotoxicity independently of PPARγ. Energy metabolism and mitochondrial function were measured in perfused hearts isolated from C57BL/6, cardiomyocyte-specific PPARγ-deficient mice, and their littermates. Cardiac function and mitochondrial oxidative stress were measured in both in vitro and in vivo settings. Treatment of isolated hearts with RSG at the supratherapeutic concentrations of 10 and 30 μM caused myocardial energy deficiency as evidenced by the decreases in [PCr], [ATP], ATP/ADP ratio, energy charge with a concomitant cardiac dysfunction as indicated by the decreases in left ventricular systolic pressure, rates of tension development and relaxation, and by an increase in end-diastolic pressure. When incubated with tissue homogenate or isolated mitochondria at these same concentrations, RSG caused mitochondrial dysfunction as evidenced by the decreases in respiration rate, substrate oxidation rates, and activities of complexes I and IV. RSG also increased complexes I- and III-dependent O₂⁻ production, decreased glutathione content, inhibited superoxide dismutase, and increased the levels of malondialdehyde, protein carbonyl, and 8-hydroxy-2-deoxyguanosine in mitochondria, consistent with oxidative stress. N-acetyl-L-cysteine (NAC) 20 mM prevented RSG-induced above toxicity at those in vitro settings. Cardiomyocyte-specific PPARγ deletion and PPARγ antagonist GW9662 did not prevent the observed cardiotoxicity. Intravenous injection of 10 mg/kg RSG also caused cardiac dysfunction and oxidative stress, 600 mg/kg NAC antagonized these adverse effects. In conclusion, this study demonstrates that RSG at supratherapeutic concentrations causes cardiotoxicity via a PPARγ-independent mechanism involving oxidative stress-induced mitochondrial dysfunction in mouse hearts.
44
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · New England Journal of Medicine · 2007 · 763 citations · Full text
Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I
Barbara Brunmair, Katrin Staniek, Nicole Scharf et al. · Diabetes · 2004 · 518 citations · Full text
Evidence for a Potent Antiinflammatory Effect of Rosiglitazone
Priya Mohanty, Ahmad Aljada, Husam Ghanim et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 381 citations · Full text
Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM
Mahmoud N. Ghazzi, Julio E. Pérez, Tammy K Antonucci et al. · Diabetes · 1997 · 366 citations
Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice
Ni-Huiping Son, Tae‐Sik Park, Haruyo Yamashita et al. · Journal of Clinical Investigation · 2007 · 333 citations · Full text